EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial

Marlies S Wijsenbeek iD, Shervin Assassi iD, Arata Azuma iD, Vincent Cottin iD, Anna-Maria Hoffmann-Vold iD, Toby M Maher iD, Fernando J Martinez, Justin M Oldham, Luca Richeldi iD, Claudia Valenzuela iD, Hui Gu, Ivana Ritter und 3 weitere

European Respiratory Journal · 2026-07 · 68 (1) · 2501899

DOI: 10.1183/13993003.01899-2025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 26.03.2026. Verfasst von Marlies S Wijsenbeek und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherl…. Hauptthemen laut MEDLINE: Indoles, Pulmonary Fibrosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast 9 mg twice daily and 18 mg twice daily (hereafter nerandomilast 9 mg and 18 mg, respectively) reduced the decline in forced vital capacity at week 52 compared with placebo (primary end-point). We assessed the effects of nerandomilast up to the final database lock.

Methods

Time to first acute exacerbation of interstitial lung disease, hospitalisation for respiratory cause or death (key secondary end-point) and other time-to-event end-points were assessed.

Results

1176 patients, of whom 512 were taking background nintedanib, received nerandomilast or placebo. At the final database lock, the mean± sd exposure to trial medication was 15.1±5.7 months and the mean± sd observation period was 17.0±4.1 months. Compared with placebo, the hazard ratio for the key secondary end-point was 0.78 (95% CI 0.61–1.00) for nerandomilast 9 mg and 0.77 (95% CI 0.60–0.99) for nerandomilast 18 mg; hazard ratios were lower among patients not taking nintedanib (0.69 (95% CI 0.49–0.97) and 0.65 (95% CI 0.46–0.92), respectively) than among those taking background nintedanib (0.90 (95% CI 0.63–1.30) and 0.93 (95% CI 0.65–1.34), respectively). For death, the hazard ratio versus placebo was 0.51 (95% CI 0.34–0.78) for both nerandomilast doses. Adverse events led to discontinuation of trial medication in 12.5%, 12.0% and 12.3% of the placebo, nerandomilast 9 mg and nerandomilast 18 mg groups, respectively.

Conclusions

In the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesPulmonary FibrosisHumansMaleFemaleAgedMiddle AgedFollow-Up StudiesDisease ProgressionTreatment OutcomeVital CapacityDouble-Blind MethodHospitalizationProportional Hazards ModelsCyclobutanesPiperidines

Substanzen

IndolesnintedanibnerandomilastCyclobutanesPiperidines

Autor:innen und Institutionen

  • Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands m.wijsenbeek-lourens@erasmusmc.nl.
  • Division of Rheumatology, McGovern Medical School, UTHealth Houston, Houston, TX, USA.
  • Clinical Research Center, Mihara General Hospital, Saitama, Japan.
  • Nippon Medical School, Tokyo, Japan.
  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
  • Department of Rheumatology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Marlies S Wijsenbeek, Shervin Assassi, Arata Azuma, Vincent Cottin, Anna-Maria Hoffmann-Vold, Toby M Maher, Luca Richeldi, Claudia Valenzuela

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Wijsenbeek, M. S., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A. M., Maher, T. M., Martinez, F. J., Oldham, J. M., Richeldi, L., Valenzuela, C., Gu, H., Ritter, I., Stowasser, S., Kreuter, M., & FIBRONEER-ILD Trial Investigators (2026). Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial. European Respiratory Journal, 68(1), 2501899. https://doi.org/10.1183/13993003.01899-2025

Vancouver

Wijsenbeek MS, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Maher TM, et al. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial. European Respiratory Journal. 2026;68(1):2501899. doi:10.1183/13993003.01899-2025

BibTeX
@article{Wijsenbeek2026,
  author = {Wijsenbeek, Marlies S and Assassi, Shervin and Azuma, Arata and Cottin, Vincent and Hoffmann-Vold, Anna-Maria and Maher, Toby M and Martinez, Fernando J and Oldham, Justin M and Richeldi, Luca and Valenzuela, Claudia and Gu, Hui and Ritter, Ivana and Stowasser, Susanne and Kreuter, Michael and FIBRONEER-ILD Trial Investigators, FIBRONEER-ILD Trial Investigators},
  title = {Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial},
  journal = {European Respiratory Journal},
  year = {2026},
  volume = {68},
  number = {1},
  pages = {2501899},
  doi = {10.1183/13993003.01899-2025}
}
Kostenlos starten →